6th International Young Scientist Congress (IYSC-2020) will be Postponed to 8th and 9th May 2021 Due to COVID-19. 10th International Science Congress (ISC-2020).  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

DNA-Binding and Cytotoxic activities of Supercritical-CO2 extracts of Ganoderma lucidum (Curt.:Fr.) P. Karst. collected from the Wild of Bukidnon Province, Philippines

Author Affiliations

  • 1Department of Biology, College of Arts and Sciences, Central Mindanao University, Musuan, Bukidnon, PHILIPPINES
  • 2 Dept. of Biological Sci., College of Sci. and Mathematics, Mindanao State University-Iligan Institute of Technology, Iligan City, PHILIPPINES

Int. Res. J. Biological Sci., Volume 2, Issue (3), Pages 62-68, March,10 (2013)


DNA-binding and cytotoxic natural products are of current interest for the discovery of new anticancer and/or antitumor drugs. Mushrooms in the wild such as Ganoderma lucidum (Curt.:Fr.) P. Karst. is a promising source of such bioactive natural products, thus it must be investigated for potential bioprospecting. In the present study, the bioactive compounds from the three supercritical-CO (SC-CO) extracts of G. lucidum (Curt.:Fr.) P. Karst (GL1, GL2 and GL3)collected in wild of Bukidnon Province, Philippines were tested in their ability to bind to genomic DNA in vitro and their cytotoxicity in vivo using biomolecular-chemical screening and brine shrimp lethality assay (BSLA), respectively. Results revealed that the extracts from 10 (GL1) and 30 (GL3) MPa extraction pressures contained compounds that exhibit binding affinity towards Salmon sperm DNA as indicated by their Rf/Rf ratios below 1. For BSLA, the LC50 (24h) values ranged from 31.62-89.12 µg/ml, indicate significant cytotoxic activity. Based on the results, the wild G. lucidum (Curt.:Fr.) P. Karst used could be a potential source of DNA-binding and cytotoxic compounds that can be exploited for the development of therapeutically-useful drugs for tumors and/or cancers.


  1. Gibson D., Drug-DNA interactions and novel drug design, Pharmacogenomics J., 275-276 (2002)
  2. Newman D.J., Cragg G.M. and Snader K.M., Natural products as sources of new drugs over the period 1981-2002, J. Nat. Prod.,66),1022-37 (2003)
  3. Kim J. and Park E.J., Cytotoxic Anticancer Candidates from Natural Resources, Curr. Med. Chem., 485-537 (2002)
  4. Maier A., Maul C., Zerlin M., Sattler I., Grabley S. and Thiericke R., Biomolecular-chemical screening: a novel screening approach for the discovery of biologically active secondary metabolites. I. Screening strategy and validation, J. Antibiot., 5211),945-951 (1999a)
  5. Meyer B.B., Ferrigni N.R., Putnam J.E., Jacobsen L.B., Nichols D.E. and McLaughlin J.L., Brine shrimp: a convenient general bioassay for active plant constituents, Planta Med.,45, 31-34 (1982)
  6. Petrova R.D., Reznick A.Z., Wasser S.P., Denchev C.M., Nevo E. and Mahajna J., Fungal metabolites modulating NF-B activity: An approach to cancer therapy and chemoprevention (Review), Oncology Reports, 19, 299-308 (2008)
  7. Paterson R.R.M., Ganoderma- A therapeutic fungal biofactory, Phytochem., 67, 985-2001 (2006)
  8. Wasser S.P., Reishi or Ling Zhi (Ganoderma lucidum), Encyclopedia of Dietary Supplements. 603-620 (2005)
  9. Lakshmi B., Ajith T.A., Jose N. and Janardhanan K.K., Antimutagenic activity of methanolic extract of Ganoderma lucidum and its effect on hepatic damage caused by benzo[]pyrene, J. Ethnopharmacol., 107, 297-303 (2006)
  10. Galor S.W., Tomlison B. and Benzie I.F.F., Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study, Br. J. Nutr., 91, 263-269 (2004)
  11. Wang H. and Ng T.B., Ganodermin, an antifungal protein from fruiting bodies of the medicinal mushrooms Ganoderma lucidum, Peptides, 271), 27-30 (2006)
  12. Gao Y., Zhou S., Huang M. and Xu A., Antibacterial and Antiviral Value of the Genus Ganoderma P. Karst. Species (Aphyllophoromycetidae): A Review, Int. J. Med. Mushrooms, 1-12 (2003)
  13. Wasser S.P., Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides, Appl. Microbiol. Biotechnol., 60, 258-274 (2002)
  14. Mizuno T., Ganoderma lucidum and Ganoderma tsugae: bioactive substances and medicinal effects, Food Rev. Int., 11), 151-166 (1995)
  15. Kim H.W. and Kim B.K., Biomedicinal triterpenoids of Ganoderma lucidum (Curt.: Fr.) P. Karst. (Aphyllophoromycetidae), Int J. Med. Mushrooms, 1, 121-138 (1999)
  16. Kidukuli A.W., Mbwambo Z.H., Malebo H.M., Mgina C.A. and Mihale M.J., In vivo antiviral activity, protease inhibition and brine shrimp lethality of selected Tanzanian wild edible mushrooms, J. Appl. Biosci.,31, 1887-1894 (2010)
  17. Lindequist U., Niedermeyer T.H.J. and Jlich W.D., The Pharmacological Potential of Mushrooms, eCAM, ), 285-299 (2005)
  18. Leonard A.C., Two Ganoderma species compared, Mycologist, 12), 65-68 (1998)
  19. Maier A., Maul C., Zerlin M., Sattler I., Grabley S. and Thiericke R., Biomolecular-chemical screening: a novel screening approach for the discovery of biologically active secondary metabolites. II. Application studies with pure metabolites, J. Antibiot., 5211), 952-959 (1999b)
  20. Maul C., Sattler I., Zerlin M., Hinze C., Koch C., Maier A., Grabley S. and Thiericke R., Biomolecular chemical screening: a novel screening approach for the discovery of biologically active secondary metabolites. III. New DNA-binding metabolites, J. Antibiot., 5212),1124-1134 (1999)
  21. McLaughlin J.L. and Rogers L.L., The Use of Biological Assays to Evaluate Botanicals, Drug Inf. J.,32, 513-524 (1998)
  22. Finney D.J., Probit Analysis, Cambridge University Press rd Ed., (1971)
  23. Montanher A.B.P., Pizzolatti M.G. and Brighente I.M.C., An application of the brine shrimp bioassay for general screening of Brazilian medicinal plants, Acta Farm. Bonaerense, 21(3), 175-178 (2002)
  24. Gupta M.P., Monge A., Karikas A., Lopez de Cerain A., Solis P.N., de Leon E., Trujillo M., Suarez O., Wilson F., Montenegro G., Noriega Y., Santana A.I., Correa M. and Sanchez C., Screening of Panamanian medicinal plants for brine shrimp toxicity, crown gall tumor inhibition, cytotoxicity and DNA intercalation, Int. J. Pharm.,34),19-27 (1996)
  25. 5.Van Laar E.S., Roth S., Weitman S., MacDonald J.R. and Waters S.J., Activity of Irofulven against Human Pancreatic Carcinoma Cells Lines In Vitro and In Vivo, Anticancer Res., 24, 59-66 (2004)
  26. Lin S.B., Li C.H., Lee S.S. and Kan L.S., Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest, Life Sciences, 7221), 2381-2390 (2003)
  27. Gonzalez A.G., Leon F., Rivera A., Padron J.I., Gonzalez-Plata J., Zuluaga J.C., Quintana J., Estevez F. and Bermejo J., New lanostanoids from the fungus Ganoderma concinna, J. Nat. Prod., 65, 417–421 (2002)
  28. Min B.S., Gao J.J., Nakamura N. and Hattori M., Triterpenes from the Spores of Ganoderma lucidum and Their Cytotoxicity against Meth-A and LLC Tumor Cells, Chem. Pharm. Bull.,48), 1026-1033 (2000)
  29. Gao J.J., Hirakawa A., Min B.S., Nakamura N. and Hattori M., In vivo antitumor effects of bitter principles from the antlered form of fruiting bodies of Ganoderma lucidum, J. Nat.Med., 60, 42-48 (2006)
  30. Zhou S. and Gao Y., The immunomodulating effects of Ganoderma lucidum (Curt.: Fr.) P. Karst (LingZhi, Reishi Mushroom) (Aphylloromycetidae), In. J. Med. Mushrooms, 4, 1-11 (2002)